Targeting interleukin-6 in inflammatory autoimmune diseases and cancers
- 27 September 2013
- journal article
- review article
- Published by Elsevier BV in Pharmacology & Therapeutics
- Vol. 141 (2), 125-139
- https://doi.org/10.1016/j.pharmthera.2013.09.004
Abstract
No abstract availableKeywords
This publication has 99 references indexed in Scilit:
- Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cellsCellular Signalling, 2013
- TLR3 activation evokes IL-6 secretion, autocrine regulation of Stat3 signaling and TLR2 expression in human bronchial epithelial cellsJournal of Cell Communication and Signaling, 2012
- Interleukin-6, its role in fibrosing conditionsCytokine & Growth Factor Reviews, 2012
- Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancerEuropean Journal of Cancer, 2012
- Interleukin-6 in bone metastasis and cancer progressionEuropean Journal of Cancer, 2010
- Mechanisms Underlying Inflammation in NeurodegenerationCell, 2010
- Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open‐label phase I dosage‐escalation studyArthritis & Rheumatism, 2010
- The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancerTrends in Molecular Medicine, 2008
- Signal transduction pathways and transcriptional regulation in the control of Th17 differentiationSeminars in Immunology, 2007
- IL6 genotypes and colon and rectal cancerCancer Causes & Control, 2007